We were delighted to participate in the Entrepreneurship Series 2026 organised by the Hong Kong Life Sciences Society (HKLSS), where our Principal, Pauli Wong, delivered a session on "Patent Strategy for Life Sciences Spinouts: From Discovery to Deal-Ready IP". Pauli shared practical insights into the various forms of IP and patent protection available to innovators, key considerations for safeguarding life sciences inventions, and the unique IP opportunities and challenges facing businesses operating across the Greater Bay Area (GBA).

Thank you to HKLSS for the invitation and to all attendees for the engaging discussion. Eagle IP remains committed to supporting innovation, entrepreneurship, and the growth of Hong Kong's life sciences ecosystem.

我们的过去活动

BioHK2026 | Biotech IP in practice

2026年9月16日

Jennifer Che Once Again Named to the IAM Strategy 300

2026年8月21日

Yolanda Wang attended the 1st China Pharmaceutical Innovation Conference

2026年7月22日

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

2026年6月16日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

2026年6月5日

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2026年6月2日

Recommended Insights

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]
阅读更多 >

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

2018年11月12日
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]
阅读更多 >

Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics

2026年7月14日
How the Supreme People's Court Established a New Benchmark for Unexpected Technical Effects in a Landmark Diabetic Nephropathy Case Proving inventive step for pharmaceutical compounds, especially a second medical use, remains one of the most challenging aspects of patent prosecution in China. When the prior art discloses a compound's general therapeutic properties, how can an […]
阅读更多 >

First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing

2023年3月8日
What does an invention “completed” in China mean? China and the US are similar in that both countries highly value national security, and thus have rules regulating the exportation of technology and information from within their borders. This includes new inventions that arise from within their respective borders. As such, both governments require inventors who […]
阅读更多 >
Top crossarrow-right